Why Disney (DIS), Amedica (AMDA), Cvent (CVT), UniPixel (UNXL), and Repros Therapeutics (RPRX) Are Spiking Today

Cvent Going Private

Shares of Cvent Inc (NYSE:CVT) are trading up by more than 65.5% on Monday afternoon, driven by news that the company has agreed to be taken private. As per the deal, Vista Equity Partners will acquire the small-cap tech company for $36 per share or $1.65 billion in cash, a 69% premium over the stocks’ closing price on Friday.

Cvent Inc (NYSE:CVT) counted 14 hedge fund supporters among those that we track at the end of 2015. However, their stakes only accounted for 3.7% of the company’s outstanding shares. Among those 14 institutional backers was Sanford J. Colen’s Apex Capital, which held 500,100 shares of the company at the end of the fourth quarter.

UniPixel’s Roller Coaster Continues

Also on the rise today is UniPixel Inc (NASDAQ:UNXL); the stock has gained more than 19% since the market opened this morning, adding to the rally seen since its January lows, with shares now up by approximately 363% since January 26. So, what’s been going on? Well, by early January, the stock had tumbled by 95% from its April 2015 highs, mainly driven by the company’s retraction from a joint venture with Kodak, and its entry into a partnership with Atmel’s XSense, from which it also acquired assets. The recuperation seen recently seems to confirm investors’ renewed bullishness on the company and its products, which now seem much more marketable following the overhaul and general work done in 2015.

UniPixel Inc (NASDAQ:UNXL) has not attracted much hedge fund attention so far, counting only three supporters in our database as of December 31. Hudson Bay Capital Management holds the largest position disclosed as of March 31 so far, comprising 3.38 million shares of the company.

Repros Continues to Rally on Proellex’s Results

Finally, there’s Repros Therapeutics Inc (NASDAQ:RPRX), which is up by 14.75% in Monday trading, continuing with the recent rally the stock witnessed; shares are up by more than 187% over the past five trading days. The rush was set in motion by the announcement of successful results from the company’s Phase 2b clinical trial evaluating Proellex’s ability to reduce excessive menstrual bleeding in women with uterine fibroids (UF).

Repros Therapeutics Inc (NASDAQ:RPRX) counted the support of Alex Denner’s Sarissa Capital Management, which held more than 1.00 million shares of the company on December 31, plus that of another nine funds in our database.

Disclosure: Javier Hasse holds no positions in any of the securities mentioned in this article.